Clinical Trial Search

Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…

Primary: 2 Year Progression Free Percent — 62.5 percentage of participants

Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants

Primary: Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy — 50 Participants

Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)

Primary: Percent of Patients Who Are Progression Free at 2 Years — 45.0; 36.4 percentage of participants

Primary: Rate of Patients Achieving an Objective Response — 0; 0 participants

Primary: One-Year Progression-Free Survival (PFS) Rate — 84.5; 74.4 Percentage of participants

Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants

Primary: Linear Regression of Maximal Percent Reduction in Serum Monoclonal (M) Protein on Baseline Percent CD56^Dim Cells in Bone Marrow — -2.562; 2.464; 0.274 % chg from BL in…

Primary: Confirmed Overall Response Rate (Stringent Complete Response [sCR], Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) With Single…

Primary: Changes in M-protein Levels — 1.65; 2.24 g/dL — p=.23

Primary: Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months…

Primary: Maximum Tolerated Dose (MTD) — 1600 cGy

Primary: Objective Response Rate — 6; 16; 11; 10 Participants

Primary: Percentage of Participants Who Achieved a Complete Response (CR) by International Myeloma Working Group (IMWG) Criteria — 4.9; 12.2; 0 percentage of participants

Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma. — 84.6; 83.3 percentage of participants

Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 15 percentage of participants

Primary: Maximum Tolerated Dose (MTD) — 20 mg LBH589

Primary: Progression Free Survival — 3; 9 participants

Primary: Immune Response — 7 Particpants

Primary: Median Progression Free Survival (mPFS) — 76.4 months

Primary: Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation…

Primary: Number of Participants With Pulmonary Toxicity — 32 Participants

Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants

Primary: Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy — 13 percentage of participants

Primary: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants — 27; 24 percentage of participants — p=0.4859

Primary: Overall Response Rate (ORR) — 1; 1; 7; 1 participants

Primary: Overall Response Rate — 95 percentage of participants